Skip to Main Content

Paper Details

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure.
Ann Oncol
19
2020
-HSD2, 11-HSD2, 11-hydroxysteroid, 11-hydroxysteroid dehydrogenase-2, AR, CRPC, Enzalutamide, Human, PATIENTS, Patients, androgen, androgen receptor, apalutamide, cortisol, cortisone, enzalutamide, leuprolide, men, metastatic CRPC, metastatic and non-metastatic prostate cancer, metastatic castration-resistant prostate cancer, non-metastatic castration-sensitive prostate cancer, prostate, prostate cancer, renal 11-HSD2, tetrahydrocortisol, tetrahydrocortisone
Author NameAffiliation
Michael BerkGenitourinary Malignancies Research Center, Lerner Research Institute, Cleveland Clinic
Edwin M PosadasSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic
  • 1 - 3

Datasets

Release 1.2